作者
Harshabad Singh,Pranshu Sahgal,Kevin S. Kapner,Steven M. Corsello,Hersh Gupta,Rahul Gujrathi,Yvonne Li,Andrew D. Cherniack,Raquelle El Alam,Joseph Kerfoot,Elizabeth Andrews,Annette Lee,Chetan Nambiar,Alison M. Hannigan,Joshua Remland,Lauren K. Brais,Michael Leahy,Douglas A. Rubinson,Benjamin L. Schlechter,Matthew Meyerson,Yanan Kuang,Cloud P. Paweletz,Jessica Lee,Júlia C. F. Quintanilha,Andrew J. Aguirre,Kimberly Perez,Brandon M. Huffman,Humberto Rossi,Thomas A. Abrams,Sheheryar Kabraji,Livio Trusolino,Andrea Bertotti,Ewa T. Sicinska,Aparna R. Parikh,Brian M. Wolpin,Alexa B. Schrock,Marios Giannakis,Kimmie Ng,Jeffrey A. Meyerhardt,Jason L. Hornick,Nilay Sethi,James M. Cleary
摘要
Abstract Purpose: ERBB2 amplified colorectal cancer (CRC) is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. CRC cohorts with genomic profiling were used to identify ERBB2 amplified cases (Dana-Farber, n = 47/2,729 [1.7%]; FMI, n = 1857/49,839 [3.7%]). Outcomes of patients receiving HER2-directed therapies are reported (Dana-Farber, n = 9; Flatiron Health-Foundation Medicine clinicogenomic database, FH-FMI CGDB, n = 38). Multi-site HER2 immunohistochemistry and genomic profiling were performed to understand HER2 intratumoral and interlesional heterogeneity. The impact of concurrent RAS co-mutations on the effectiveness of HER2-directed therapies were studied in isogenic CRC cell lines and xenografts. Results: ERBB2 amplifications are enriched in left-sided CRC. 20% of ERBB2 amplified CRCs have co-occurring oncogenic RAS/RAF alterations. While RAS/RAF wild-type CRC typically have clonal ERBB2 amplification, CRCs with co-occurring RAS/RAF alterations have lower level ERRB2 amplification, higher intratumoral heterogeneity, and interlesional ERBB2 discordance. These distinct genomic patterns lead to differential responsiveness and patterns of resistance to HER2-directed therapy. ERBB2 amplified CRC with RAS/RAF alterations are resistant to trastuzumab-based combinations, such as trastuzumab/tucatinib, but retain sensitivity to trastuzumab deruxtecan in in vitro and murine models. Trastuzumab deruxtecan shows clinical efficacy in cases with high-level ERBB2 amplified RAS/RAF co-altered CRC. Conclusions: Co-occurring RAS/RAF alterations define a unique subtype of ERBB2 amplified CRC that has increased intratumoral heterogeneity, interlesional discordance and resistance to trastuzumab-based combinations. Further examination of trastuzumab deruxtecan in this previously understudied cohort of ERBB2 amplified CRC is warranted.